

EMA/336630/2023

European Medicines Agency decision P/0304/2023

of 11 August 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for repagermanium, (EMEA-003154-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0304/2023

of 11 August 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for repagermanium, (EMA-003154-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Dimerix Bioscience Pty Ltd. on 14 December 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 June 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for repagermanium, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for repagermanium, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for repagermanium, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Dimerix Bioscience Pty Ltd, 425 Smith Street, 3065 - Fitzroy, Victoria, Australia.

EMA/PDCO/152134/2023
Amsterdam, 23 June 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003154-PIP01-21

Scope of the application

Active substance(s):

Repagermanium

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of focal segmental glomerulosclerosis

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Dimerix Bioscience Pty Ltd.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Dimerix Bioscience Pty Ltd. submitted for agreement to the European Medicines Agency on 14 December 2021 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 31 January 2022.

Supplementary information was provided by the applicant on 20 March 2023. The applicant proposed modifications to the paediatric investigation plan and requested a deferral.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of focal segmental glomerulosclerosis

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- capsule, hard, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of focal segmental glomerulosclerosis

2.1.1. Indication(s) targeted by the PIP

Treatment of focal segmental glomerulosclerosis in paediatric patients aged 1 year to less than 18 years who are concomitantly being treated with an angiotensin receptor blocker.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age-appropriate capsule formulation
Non-clinical studies	Not applicable
Clinical studies	Study 2 Double-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics, efficacy and safety of repagermanium in paediatric patients from 12 years to less than 18 years of age (and adults) with focal segmental glomerulosclerosis (DMX-200-301) Study 3 Open-label, single-arm trial to evaluate safety, tolerability, pharmacokinetics and activity of repagermanium in paediatric

	patients from 1 year to less than 12 years of age with focal segmental glomerulosclerosis
Modelling and simulation studies	Study 4 Population PK modelling and simulation study to evaluate the use of repagermanium in paediatric patients from 1 year to less than 18 years of age with focal segmental glomerulosclerosis (DMX-200-301 PK modelling) Study 5 Modelling and simulation study to extrapolate efficacy of repagermanium from adults and adolescents to paediatric patients from 1 year to less than 12 years of age with focal segmental glomerulosclerosis (DMX-200-301 PD modelling)
Other studies	Not applicable
Extrapolation plan	Study 2 (DMX-200-301), Study 3, Study 4 (DMX-200-301 PK modelling) and Study 5 (DMX-200-301 PD modelling) are part of an extrapolation plan covering the paediatric population from 1 year to less than 12 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By July 2031
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.